VALBIOTIS |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.9 EUR | -1.64% |
|
+0.91% | -22.00% |
| Apr. 26 | Valbiotis SA Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Apr. 03 | Valbiotis: launch of Valbiotis PRO Cholesterol in May | CF |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
VALBIOTIS is a French Research & Development company committed to scientific innovation for the prevention and control of metabolic diseases. Valbiotis specializes in the development of innovative nutritional solutions for cardio-metabolic disease prevention and nutritional support for patients. The products are intended for food and pharmaceutical industries. Valbiotis is essentially intervening in the prevention of type 2 diabetes, NASH (non-alcoholic steatohepatitis), obesity and cardiovascular diseases.
VALBIOTIS has established numerous partnerships with academic centers of excellence in France and overseas, including the University of La Rochelle, the CNRS, and the Clermont Auvergne University in Clermont-Ferrand where the company has opened a secondary school. With these agreements, since its inception Valbiotis has benefited from a strong leverage thanks notably to experts and technical partners involved in its projects.
Calendar
2024-04-28
- Q4 2023 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
3.9
EUR
Average target price
10.07
EUR
Spread / Average Target
+158.12%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -22.00% | 65.67M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.74B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- ALVAL Stock
- News VALBIOTIS
- Valbiotis CFO To Step Down In June
